Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Anliker-Ort

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Drug Investigation|October 19, 2023
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy SubjectsMarion Anliker-Ort, Jasper Dingemanse, Luboš Janů, et al.
Frontiers in Immunology|December 28, 2020
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement PathwayMarion Anliker-Ort, Jasper Dingemanse, John van den Anker, et al.
Journal of Clinical Pharmacology|May 12, 2024
Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating WomenPriska Kaufmann, Clemens Muehlan, Marion Anliker-Ort, et al.
British Journal of Clinical Pharmacology|August 24, 2022
Multiple-ascending doses of ACT-1014-6470, an oral complement factor 5a receptor 1 (C5a<sub>1</sub> receptor) antagonist: Tolerability, pharmacokinetics and target engagementMarion Anliker-Ort, Jasper Dingemanse, Hervé Farine, et al.
Clinical and Translational Science|April 12, 2023
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT-1014-6470 in vitro and in vivoMarion Anliker-Ort, Jasper Dingemanse, Stephane Delahaye, et al.
Pharmacology Research & Perspectives|July 20, 2023
Modeling time-delayed concentration-QT effects with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5a<sub>1</sub> receptor) antagonistMarion Anliker-Ort, Chih-Hsuan Hsin, Andreas Krause, et al.
Journal of Clinical Pharmacology|March 18, 2024
Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva - A Case StudyMarion Anliker-Ort, Frédérique Rodieux, Victoria C Ziesenitz, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Drug Investigation|October 19, 2023
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy SubjectsMarion Anliker-Ort, Jasper Dingemanse, Luboš Janů, et al.
Frontiers in Immunology|December 28, 2020
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement PathwayMarion Anliker-Ort, Jasper Dingemanse, John van den Anker, et al.
Journal of Clinical Pharmacology|May 12, 2024
Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating WomenPriska Kaufmann, Clemens Muehlan, Marion Anliker-Ort, et al.
British Journal of Clinical Pharmacology|August 24, 2022
Multiple-ascending doses of ACT-1014-6470, an oral complement factor 5a receptor 1 (C5a<sub>1</sub> receptor) antagonist: Tolerability, pharmacokinetics and target engagementMarion Anliker-Ort, Jasper Dingemanse, Hervé Farine, et al.
Clinical and Translational Science|April 12, 2023
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT-1014-6470 in vitro and in vivoMarion Anliker-Ort, Jasper Dingemanse, Stephane Delahaye, et al.
Pharmacology Research & Perspectives|July 20, 2023
Modeling time-delayed concentration-QT effects with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5a<sub>1</sub> receptor) antagonistMarion Anliker-Ort, Chih-Hsuan Hsin, Andreas Krause, et al.
Journal of Clinical Pharmacology|March 18, 2024
Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva - A Case StudyMarion Anliker-Ort, Frédérique Rodieux, Victoria C Ziesenitz, et al.
Pageof 1